

April 28, 2026



Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029.

The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy.

Accreditation Scope and Verification

The FACT certificate confirms that Cryo-Cell International, Inc., having met the NetCord-FACT Standards for Cord Blood Banking, is granted FACT Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations.

To verify the official FACT accreditation and other licenses, visit:

<https://www.cryo-cell.com/healthcare-providers/accreditations-licenses>

Why FACT Accreditation Matters

FACT is an independent, internationally recognized accrediting body. Its standards are used by the nation’s leading transplant and cancer centers when selecting cord blood units from public banks.

Cryo-Cell International, Inc. was the first U.S. private (family-use) cord blood bank to receive FACT accreditation — a pioneering commitment to peer-reviewed, expert-developed standards that exceed regulatory minimums, and have been independently validated through continuous accreditation for more than a decade.

FACT accreditation requires a rigorous on-site inspection by qualified experts, comprehensive documentation review, and demonstrated compliance across collection, processing, testing, storage, and release protocols.

Executive Statement

“FACT accreditation is the standard used by the world’s leading transplant centers for evaluating public cord blood banks. Earning and renewing this credential for private banking demonstrates that the Company operates at that same level of rigor — giving families and their physicians an independently verified quality benchmark they can trust.”

— David Portnoy, Co-CEO, Cryo-Cell International, Inc.

Cryo-Cell’s Commitment to Quality and Safety

In addition to FACT accreditation, Cryo-Cell International, Inc.’s facility is:

- FDA-registered and cGMP-/cGTP-compliant
- AABB accredited as a cord blood banking facility
- Licensed in all states requiring licensure
- National Marrow Donor Program (NMDP) network cord blood bank

The Company holds exclusive rights to PrepaCyte-CB, an advanced FDA 510k cord blood processing technology designed to maximize stem cell recovery and viability.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. The Company, together with its global affiliates, stores more than 250,000 cord blood and cord tissue specimens for the exclusive benefit of newborn babies and their families. In addition to its private bank, Cryo-Cell International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 900 transplants and operates a cord blood donation site at one of the country’s most prominent hospitals, Cedars–Sinai Hospital in Los Angeles, California. Cryo-Cell’s facility is FDA-registered, cGMP-/cGTP-compliant, and licensed in all states requiring licensure. In addition to AABB accreditation as a cord blood facility, Cryo-Cell was the first U.S. private (family-use) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell holds exclusive rights to PrepaCyte-CB, the industry’s most advanced cord blood processing technology. Cryo-Cell’s mission is to provide clients with the premier cord blood and cord tissue cryopreservation service and to aid in the advancement of regenerative medicine.

For more information, visit www.cryo-cell.com or contact Irene Smith at ismith@cryo-cell.com / 813-749-2102.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20260428302908/en/>

Irene Smith

Phone: 813-749-2102

Email: ismith@cryo-cell.com

Source: Cryo-Cell International, Inc.